Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Surveillance of pneumococcal diseases in Central and Eastern Europe

M. Ceyhan, R. Dagan, A. Sayiner, L. Chernyshova, EÇ. Dinleyici, W. Hryniewicz, A. Kulcsár, L. Mad'arová, P. Pazdiora, S. Sidorenko, A. Streinu-Cercel, A. Tambić-Andrašević, L. Yeraliyeva,

. 2016 ; 12 (8) : 2124-2134. [pub] 20160420

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc18017296

Pneumococcal infection is a major cause of morbidity and mortality worldwide. The burden of disease associated with S. pneumoniae is largely preventable through routine vaccination. Pneumococcal conjugate vaccines (e.g. PCV7, PCV13) provide protection from invasive pneumococcal disease as well as non-invasive infection (pneumonia, acute otitis media), and decrease vaccine-type nasopharyngeal colonisation, thus reducing transmission to unvaccinated individuals. PCVs have also been shown to reduce the incidence of antibiotic-resistant pneumococcal disease. Surveillance for pneumococcal disease is important to understand local epidemiology, serotype distribution and antibiotic resistance rates. Surveillance systems also help to inform policy development, including vaccine recommendations, and monitor the impact of pneumococcal vaccination. National pneumococcal surveillance systems exist in a number of countries in Central and Eastern Europe (such as Croatia, Czech Republic, Hungary, Poland, Romania and Slovakia), and some have introduced PCVs (Czech Republic, Hungary, Kazakhstan, Russia, Slovakia and Turkey). Those countries without established programs (such as Kazakhstan, Russia and Ukraine) may be able to learn from the experiences of those with national surveillance systems. The serotype distributions and impact of PCV13 on pediatric pneumococcal diseases are relatively similar in different parts of the world, suggesting that approaches to vaccination used elsewhere are also likely to be effective in Central and Eastern Europe. This article briefly reviews the epidemiology of pneumococcal disease, presents the latest surveillance data from Central and Eastern Europe, and discusses any similarities and differences in these data as well the potential implications for vaccination policies in the region.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18017296
003      
CZ-PrNML
005      
20180515103121.0
007      
ta
008      
180515s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1080/21645515.2016.1159363 $2 doi
035    __
$a (PubMed)27096714
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Ceyhan, Mehmet $u a Department of Pediatric Infectious Diseases , School of Medicine, Hacettepe University , Ankara , Turkey.
245    10
$a Surveillance of pneumococcal diseases in Central and Eastern Europe / $c M. Ceyhan, R. Dagan, A. Sayiner, L. Chernyshova, EÇ. Dinleyici, W. Hryniewicz, A. Kulcsár, L. Mad'arová, P. Pazdiora, S. Sidorenko, A. Streinu-Cercel, A. Tambić-Andrašević, L. Yeraliyeva,
520    9_
$a Pneumococcal infection is a major cause of morbidity and mortality worldwide. The burden of disease associated with S. pneumoniae is largely preventable through routine vaccination. Pneumococcal conjugate vaccines (e.g. PCV7, PCV13) provide protection from invasive pneumococcal disease as well as non-invasive infection (pneumonia, acute otitis media), and decrease vaccine-type nasopharyngeal colonisation, thus reducing transmission to unvaccinated individuals. PCVs have also been shown to reduce the incidence of antibiotic-resistant pneumococcal disease. Surveillance for pneumococcal disease is important to understand local epidemiology, serotype distribution and antibiotic resistance rates. Surveillance systems also help to inform policy development, including vaccine recommendations, and monitor the impact of pneumococcal vaccination. National pneumococcal surveillance systems exist in a number of countries in Central and Eastern Europe (such as Croatia, Czech Republic, Hungary, Poland, Romania and Slovakia), and some have introduced PCVs (Czech Republic, Hungary, Kazakhstan, Russia, Slovakia and Turkey). Those countries without established programs (such as Kazakhstan, Russia and Ukraine) may be able to learn from the experiences of those with national surveillance systems. The serotype distributions and impact of PCV13 on pediatric pneumococcal diseases are relatively similar in different parts of the world, suggesting that approaches to vaccination used elsewhere are also likely to be effective in Central and Eastern Europe. This article briefly reviews the epidemiology of pneumococcal disease, presents the latest surveillance data from Central and Eastern Europe, and discusses any similarities and differences in these data as well the potential implications for vaccination policies in the region.
650    12
$a epidemiologické monitorování $7 D062665
650    _2
$a Evropa $x epidemiologie $7 D005060
650    _2
$a zdravotní politika $7 D006291
650    _2
$a lidé $7 D006801
650    _2
$a očkovací programy $7 D017589
650    _2
$a pneumokokové infekce $x epidemiologie $x prevence a kontrola $7 D011008
650    _2
$a pneumokokové vakcíny $x aplikace a dávkování $x imunologie $7 D022242
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Dagan, Ron $u b Pediatric Infectious Disease Unit, Ben-Gurion University of the Negev , Beer-Sheva , Israel.
700    1_
$a Sayiner, Abdullah $u c Department of Chest Diseases , Ege University Faculty of Medicine , Izmir , Turkey.
700    1_
$a Chernyshova, Liudmyla $u d Department of Pediatric Infectious Diseases and Immunology , National Medical Academy for Postgraduate Education , Kiev , Ukraine.
700    1_
$a Dinleyici, Ener Çağrı $u e Eskisehir Osmangazi University Faculty of Medicine , Eskisehir , Turkey.
700    1_
$a Hryniewicz, Waleria $u f National Medicines Institute, Division of Clinical Microbiology and Infection Prevention , Warsaw , Poland.
700    1_
$a Kulcsár, Andrea $u g Department of Infectology , Joint Hospital Saint László and Saint István , Budapest , Hungary.
700    1_
$a Mad'arová, Lucia $u h National Reference Centre for Pneumococcal and Haemophilus Diseases, Regional Authority of Public Health , Banská Bystrica , Slovak Republic.
700    1_
$a Pazdiora, Petr $u i Department of Epidemiology , Charles University Faculty Hospital , Pilsen , Czech Republic.
700    1_
$a Sidorenko, Sergey $u j Research Institute of Children's Infection , St. Petersburg , Russia.
700    1_
$a Streinu-Cercel, Anca $u k Carol Davila University of Medicine and Pharmacy , Bucharest , Romania.
700    1_
$a Tambić-Andrašević, Arjana $u l Department of Clinical Microbiology , University Hospital for Infectious Diseases , Zagreb , Croatia.
700    1_
$a Yeraliyeva, Lyazzat $u m Research Institute of Fundamental and Applied Medicine, Asfendiyarov Kazakh National Medical University , Almaty , Kazakhstan.
773    0_
$w MED00181409 $t Human vaccines & immunotherapeutics $x 2164-554X $g Roč. 12, č. 8 (2016), s. 2124-2134
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27096714 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20180515103255 $b ABA008
999    __
$a ok $b bmc $g 1300920 $s 1014136
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 12 $c 8 $d 2124-2134 $e 20160420 $i 2164-554X $m Human vaccines & immunotherapeutics $n Hum Vaccin Immunother $x MED00181409
LZP    __
$a Pubmed-20180515

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace